Welcome to IsraPharm - Contact us at +972 7337 468 45 (Office)

Contact Us

Office Address

Weizman 14 st., Tel Aviv, Israel

Phone Number

+972 7337 46845 (Office)

Email Address

[email protected]



In Stock

Add to Wishlist
Add to Wishlist


The FDA has approved Novartis’ Odomzo to treat locally advanced basal cell carcinoma in adults. The drug is approved for use in patients whose tumors have recurred after surgery or radiation therapy, as well as for use in patients who are not candidates for surgery or radiation therapy.

Odomzo (sonidegib) is an inhibitor of the Hedgehog signaling pathway. Inhibition of this pathway can stop or reduce the growth of cancer.

Active ingredient: sonidegib

Prescription medicine